Osteoporosis is an important risk factor for fragility fractures. Although osteoporosis is considered common in multiple sclerosis (MS), few previous studies focused on fractures in MS.
questions. 3 We asked participants about use of bisphosphonates, calcitonin, multivitamins with vitamin D, and calcium or vitamin D supplements.
We limited the analysis to US participants to minimize heterogeneity due to differences in access to care (n ϭ 15,529), and to participants with a reported age at MS symptom onset be-tween 10 and 60 years (n ϭ 14,397), because these extremes of onset groups may be atypical.
We evaluated demographic and clinical predictors of osteoporosis, bone density testing, and osteoporosis treatment using 2 tests for categorical variables, t tests for normally distributed continuous variables, and multivariable logistic regression. Multivariable models considered the variables described above and age; sex; race; socioeconomic status (SES) as measured by education, income, and health insurance status; and region of residence as previously described. 2 All statistical analyses were conducted using SAS V9.1.3.
Standard protocol approvals, registrations, and patient consents. The NARCOMS Registry is approved by the Western Institutional Review Board. Participants give permission for their information to be used for research purposes.
RESULTS
Of 14,397 eligible participants, 9,346 (64.9%) responded. Most responders were white (93.9%), were women (76.1%), had moderate disability (median PDDS 3, IQR [1-5]), and had mean (SD) age of 53.6 (10.3) years and mean (SD) disease duration of 23.0 (11.5) years. As compared to nonresponders, responders were more likely to be white, with higher levels of education and income (all p Ͻ 0.0001).
Among responders, 1,386/9,029 (15.4%) reported osteoporosis, while 1,507/8,820 (17.1%) reported osteopenia. Collectively, 2,501 (27.2%) responders reported low bone mass. The odds of osteoporosis were higher in women than men, and increased steadily with increasing age and higher levels of disability (table 1) .
Smoking, race, SES, and use of anticonvulsants were not associated with osteoporosis.
Sixteen percent of responders reported a fracture after age 13 years (n ϭ 1,482), of whom 522 (35.2%) reported a wrist fracture, 165 (11.1%) reported a vertebral fracture, 100 (7.4%) reported a Because age over 50 years is a strong fracture risk factor in the general population, we stratified other risk factors by age and sex (table 2). Risk factors for fracture were common, with impaired mobility affecting 66% of responders. More than half of responders reported a fall in the last 12 months, and 60% of participants with osteopenia or osteoporosis fell in the last year. Twenty-four percent of participants reporting low bone mass reported a fracture vs 13.1% of participants reporting normal bone mass (p Ͻ 0.0001). Twentynine percent of participants who reported both a fall in the last year and low bone mass reported a prior fracture vs 10.2% of participants with normal bone mass and no history of falls (p Ͻ 0.0001). Excluding age but including fractures over age 50 years, 1,413 (15.1%) participants had 1 risk factor for fracture, 2,341 (25.0%) had 2, and 5,393 (57.7%) had 3 or more. The probability of reporting a prior fracture increased with the number of risk factors reported (test for linear trend, p Ͻ 0.0001).
Slightly more than half of participants (n ϭ 4,675) had bone density testing. Women (60.5%) were more likely than men (21.9%) to report testing ( p Ͻ 0.0001). Several factors were independently associated with increased odds of having bone density testing and these differed between men and women as shown in table 3. We noted racial and socioeconomic disparities; among men, participants with private health insurance were more likely to report testing than those with public insurance. Among women, the odds of bone density testing were higher among whites and those with higher levels of income and education.
Overall, 4,329 (49.8%) participants used calcium supplements, 5,341 (66.3%) used vitamin D supplements or a multivitamin with vitamin D, 1,337 (14.3%) used a bisphosphonate, and 61 (0.76%) used calcitonin. Eighty-two percent of participants with osteoporosis used supplemental vitamin D or a multivitamin, while 563 (54.4%) used a bisphosphonate. Among participants with a prior fracture, 746 (55%) used calcium supplements, 858 (68.8%) used vitamin D supplements or a multivitamin with vitamin D, 334 (22.5%) used a bisphosphonate, and 50 (2.4%) used calcitonin. DISCUSSION More than 25% of participants reported osteopenia or osteoporosis. In MS, osteoporosis risk may reflect impaired mobility, lack of weight-bearing physical activity, low vitamin D levels, or other factors. 6 Osteoporosis is a risk factor for fragility fractures. 1 More than 15% of our cohort reported fractures, consistent with earlier studies. 7 Given these findings, fracture prevention is an important issue. Osteoporotic fractures are associated with substantial morbidity and mortality. 1 Often, NARCOMS participants had multiple clinical risk factors for fracture, including potentially modifiable factors such as low bone mass and falls. Regular physical activity, adequate calcium and vitamin D intake, maintaining a healthy weight, falls prevention, and avoiding smoking and heavy alcohol consumption are important for bone health. 1 In one study, only 48% of Americans met recommendations for supplemental calcium intake. 8 Our cohort reported a similar frequency of supplemental calcium intake, which was slightly higher in those with a prior history of fracture but still lower than recommended. 1 Fifty-one percent of participants reported having bone density testing and this varied with SES. This is consistent with a study of low income minorities with MS, in which one-third had inadequate preventive care for osteoporosis. 9 Previously we reported socioeconomic and racial disparities in the management of bladder symptoms in MS. 2 Several study limitations should be noted. The response rate was 65%, nonresponders differed from responders, and participants were volunteers; thus our findings may not generalize to all patients with MS. Our data were self-reported, possibly causing misclassification, but the literature supports the accuracy of self-reported osteoporosis and fracture history. 10 We did not evaluate the impact of lifetime corticosteroid use, nor examine specific doses of vitamin D. Falls or fractures may lead to knowledge of having osteoporosis or osteopenia, thus potentially leading to a diagnosis bias in those without fractures or falls.
Patients with MS frequently have multiple risk factors for fractures. Many patients with MS with low bone mass and previous fractures are not taking supplemental calcium or vitamin D, suggesting a potential area of improvement in care. A focused research agenda leading to clinical practice guidelines to optimize bone health in patients with MS is needed.
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